5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
J. Randolph Hecht(Ontario Institute for Cancer Research), Albrecht Kretzschmar(Roche (Switzerland)), Jolanda Paolini(Pfizer (Italy)), Takayuki Yoshino(University of Tsukuba), Xun Lin(Pfizer (United States)), María José Lechuga(Pfizer (Italy)), Edna Chow Maneval(Dana (United States)), Edith Mitchell(Thomas Jefferson University), Manfred Welslau(Praxis für Hämatologie und Onkologie)
Cited by 10
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k